Congrats to the incoming AJKD editorial interns! Just finished my last editorial call as a 2024-2025 intern and it was such a fantastic experience. Highly recommend to anyone interested in a research career. Very grateful to everyone on the @ajkd.bsky.social editorial board for teaching us so much!

Answer: - in centre HD, of course. But driven by: patient transportation to the unit 3 X week! #NephSky Source: @kireports.bsky.social www.ajkd.org/article/S027...

"How do you figure that out if you’ve just run a large-scale randomized experiment?" In this Medical News article, economist Susan Athey discusses the effectiveness of machine learning in targeting interventions. #MedSky

This #ASNKidneyNews policy update highlights two ongoing reforms in policy and quality programs: 1. Reform to the Centers for Medicare and Medicaid End-Stage Renal Disease Prospective Payment System. 2. Transparency and Medicare Advantage, focusing on quality. kidney.pub/KN1706-07#ASNKidneyNews

Survival advantages of deceased-donor kidney transplantation don't apply to all patients and donor organs, findings presented at #ERA25 suggested. #nephrology #nephsky #kidneytransplant #transplantation www.docwirenews.com/post/limited...

How do patients select dialysis facilities? Proximity? Quality? Preserving care continuity with their nephrologist? Our latest in @JAMAHealthForum suggests patients value proximity and care continuity. Quality gets sacrificed 🧵(link at end) 1/

While health regulations are usually well intentioned they often are poorly implemented Dialysis is a prime example of regulation perpetuating a consolidated industry with no market competition, poor outcomes &price gouging New in HealthAffairs Forefront 🧵1/ (link at end) x.com/Health_Affai...

Money shot below ⬇️ Compare to pts with FULL rx subsidies (who pay $0), pts with pts with Part D but NO subsidies had 10pp more rx fills, and pts with PARTIAL subsidies had 2pp more rx fills post-TDAPA. i.e., the more you paid pre-TDAPA, the more meds you filled post-policy

I hear that the phos binder roll-out has been painful thus far - but our findings suggest that covering meds under TDAPA *might* actually increase prescription fills, especially for patients subject to high OOP costs under Part D 🤞🏻

Latest publication! 🚨 TL;DR: 1) MANY patients on dialysis pay high OOP costs for drugs 💸 -- nearly 20% have NO PART D plan -- 25% have NO rx subsidies 2) Covering calcimimetics in Part B via TDAPA instead of Part D INCREASED rx fills 📈 Check out @eugelin06.bsky.social's 🧵 & our paper ⬇️

On Monday the Supreme Court hears a case that could strike down the ACA mandate that insurers cover preventive services at no cost to patients. We found that ~40 million people with private insurance use these free services, including half of enrolled women. JAMA Health Forum: ja.ma/3GcUZC6 🩺📊

Only 12% of patients receiving dialysis are currently on the transplant wait list. We estimate that over 11,000 additional organs would be needed to increase that number to 18%. ja.ma/4c0MNkj + check out the editorial too! Thx to my amazing mentors and @kidneyfund.bsky.social for their support.

Congrats to both of you!!! 👏🏻👏🏻👏🏻

We are excited to announce the 2025 AKF Clinical Scientist in Nephrology (CSN) fellows! Join us in congratulating Dr. Momen Abbasi, a nephrology fellow at the University of Illinois Chicago & Dr. Api Chewcharat, a nephrology fellow at @mgbresearch.bsky.social: www.kidneyfund.org/article/amer...

#NephMadness 2025: The PodCrawl buff.ly/p3xR3cg Podcasts: - @thecurbsiders.bsky.social - Life as a Nephrology Professional @nkf-professionals.bsky.social - GN in Ten - @rheummadness.bsky.social - @freelyfiltered.bsky.social - Poison Lab - Nephron Segment - Kidney Chronicles

Life Years from Transplant (LYFT) is a measure of the predicted difference between the expected lifespan with and without a kidney transplant. This study found that less homogenous metrics with meaningful disaggregation are needed to inform institutional evaluation and policy change. bit.ly/KID0710